Novartis tried to undermine publicly funded trials of Avastin in AMD, says BMJ
This article was originally published in Scrip
In the latest round of the sparring over whether Roche's Avastin (bevacizumab) should be used off-label in place of Novartis's more expensive Lucentis (ranibizumab) in wet age-related macular degeneration, the British Medical Journal has published a series of articles suggesting that Novartis hindered UK public clinical trials comparing the two drugs in order to maintain sales of Lucentis.
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.